A Bright Spot In Biotech’s Tough Year, Immunocore Looks To Build On Kimmtrak Success
Commercial Success For Orphan Cancer Drug
Executive Summary
Immunocore looked set to be another UK biotech disappointment, before it turned around its fortunes with the launch of Kimmtrak. CEO Bahija Jallal talked to Scrip about how she has steered the company to commercial success with its debut product.
You may also be interested in...
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
Pharming’s Portfolio Grows As Ultra-Rare Disease Drug Joenja Is Approved
The first ever approval for ultra-rare immunodeficiency disease APDS gives Pharming its second product on the market but patient diagnosis will be a major challenge.